The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase …
The debut financing, backed by RA Capital, Leaps by Bayer and PureTech Health, will fund a head-to-head Phase …
Efanesoctocog alfa’s extended half-life offers Australian patients a substantially reduced infusion burden compared with existing factor VIII replacement …
Genmab and AbbVie’s bispecific antibody met its primary endpoint in a head-to-head comparison, positioning the CD3xCD20 therapy for …
Gene-edited cell therapy exagamglogene autotemcel extends to pediatric patients as young as two, based on trial data showing …
The diversifying epilepsy pipeline is finally addressing inhibitory deficits that sodium channel drugs can’t touch
The approval of efanesoctocog alfa brings an extended half-life factor VIII replacement to the Australian market, arriving as …
The Series A financing backs a monoclonal antibody licensed from a Chinese biotech, betting that blocking a different …
The supplemental approval for exagamglogene autotemcel gives families of children with recurrent vaso-occlusive crises a one-time gene-editing option …
The donor-derived cell therapy is designed to be infused alongside a stem cell transplant, aiming to reduce a …
The bispecific antibody paired with lenalidomide showed a statistically significant improvement over standard care in patients with relapsed …
